SNCB is thought to function as a physiological inhibitor of SNCA in neurodegenerative diseases [36, 37], and it retains antiapoptotic ability in a dose-dependent manner [23], and β-synuclein-derived peptides behave as antiaggregating agents [25]_ENREF_7. The gene discussed is SNCB; the disease is neurodegenerative disease.